Health ❯ Clinical Research

Trial Phases

Phase 3 Trials Phase 2 Trials Safety Trials Mid-Stage Trials Efficacy Studies

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

FDA Rejects Disc Medicine’s Bitopertin for EPP After Questioning Surrogate Endpoint

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

Metsera’s Obesity Drug Posts 14% Placebo-Adjusted Weight Loss, Bolstering Pfizer Buyout Case

Acadia Halts Carbetocin for Prader-Willi After Phase 3 Miss